Selected article for: "acute illness and long covid covid"
Author: Bellucci, Gianmarco; Rinaldi, Virginia; Buscarinu, Maria Chiara; Reniè, Roberta; Bigi, Rachele; Pellicciari, Giulia; Morena, Emanuele; Romano, Carmela; Marrone, Antonio; Mechelli, Rosella; Salvetti, Marco; Ristori, Giovanni
Title: Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?
  • Cord-id: 1ijen40t
  • Document date: 2021_9_27
    • ID: 1ijen40t
    Snippet: Current knowledge on Multiple Sclerosis (MS) etiopathogenesis encompasses complex interactions between the host’s genetic background and several environmental factors that result in dysimmunity against the central nervous system. An old-aged association exists between MS and viral infections, capable of triggering and sustaining neuroinflammation through direct and indirect mechanisms. The novel Coronavirus, SARS-CoV-2, has a remarkable, and still not fully understood, impact on the immune sys
    Document: Current knowledge on Multiple Sclerosis (MS) etiopathogenesis encompasses complex interactions between the host’s genetic background and several environmental factors that result in dysimmunity against the central nervous system. An old-aged association exists between MS and viral infections, capable of triggering and sustaining neuroinflammation through direct and indirect mechanisms. The novel Coronavirus, SARS-CoV-2, has a remarkable, and still not fully understood, impact on the immune system: the occurrence and severity of both acute COVID-19 and post-infectious chronic illness (long COVID-19) largely depends on the host’s response to the infection, that echoes several aspects of MS pathobiology. Furthermore, other MS-associated viruses, such as the Epstein-Barr Virus (EBV) and Human Endogenous Retroviruses (HERVs), may enhance a mechanistic interplay with the novel Coronavirus, with the potential to interfere in MS natural history. Studies on COVID-19 in people with MS have helped clinicians in adjusting therapeutic strategies during the pandemic; similar efforts are being made for SARS-CoV-2 vaccination campaigns. In this Review, we look over 18 months of SARS-CoV-2 pandemic from the perspective of MS: we dissect neuroinflammatory and demyelinating mechanisms associated with COVID-19, summarize pathophysiological crossroads between MS and SARS-CoV-2 infection, and discuss present evidence on COVID-19 and its vaccination in people with MS.

    Search related documents:
    Co phrase search for related documents
    • acute phase and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute phase and adem disseminated encephalomyelitis: 1
    • acute phase and administration time: 1, 2, 3
    • acute phase and long covid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acute phase and long study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute phase and long term complication: 1, 2
    • acute phase and long term investigation: 1
    • acute phase and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute phase and lymphocyte subset: 1, 2, 3
    • adaptive immunity and administration time: 1
    • adaptive immunity and long covid: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • adaptive immunity and lymphocyte count: 1, 2, 3, 4, 5
    • adaptive innate and administration time: 1, 2
    • adaptive innate and long covid: 1, 2, 3, 4, 5
    • adaptive innate and long study: 1
    • adaptive innate and lymphocyte count: 1, 2
    • adaptive innate and lymphocyte subset: 1